Previous studies have shown that RIPK2 promotes the development of metastatic tumor tissues 6 and inflammatory breast cancer (IBC) 43, while the suppression of RIPK2 can hinder the migration of BC cells and reduce the occurrence of extrapulmonary metastasis 48. Here, RIPK2 is linked to neoplasm.